Naramig (Naratriptan)

Naratriptan, the active ingredient in Naramig, is a selective serotonin (5‑HT1) receptor agonist presented as an oral tablet for oral use. It is used for the acute treatment of migraine attacks in adults.

GNH USA supplies Naramig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan belongs to the triptan class and is employed for migraine management.

- Migraine attacks: provides rapid relief of headache and associated symptoms. - Migraine with aura: reduces pain intensity and duration. - Migraine without aura: alleviates headache and photophobia.

Common side effects are generally mild and transient.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: sensation of light‑headedness. - Fatigue: feeling unusually tired. - Dry mouth: reduced salivation. - Paresthesia: tingling sensations. - Somnolence: increased sleepiness.

Serious or Rare Side Effects: - Chest pain: possible cardiac discomfort. - Arrhythmia: irregular heart rhythm. - Serotonin syndrome: agitation, hyperthermia, tremor. - Severe hypertension: sudden high blood pressure. - Allergic reaction: rash, swelling, difficulty breathing. - Ischemic events: rare stroke or myocardial infarction.

Before prescribing Naramig, clinicians should evaluate patient‑specific risk factors.

- Cardiovascular assessment: review history of heart disease or uncontrolled hypertension. - Concomitant serotonergic drugs: avoid combined use with SSRIs, SNRIs, or MAO inhibitors. - Renal or hepatic impairment: adjust use based on organ function. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Storage: Store at room temperature: keep in original container, protect from moisture.

Naratriptan may interact with several medication classes.

Major Interactions (Avoid): - MAO inhibitors: risk of serotonin syndrome. - Other triptans or ergot alkaloids: increased vasoconstriction. - Linezolid: potential serotonergic toxicity.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible additive blood pressure effects. - CYP1A2 inhibitors (e.g., fluvoxamine): may raise naratriptan levels. - Oral contraceptives: may alter efficacy of migraine relief.